- Home
- AUTL vs CRGX Comparison
AUTL vs CRGX Comparison
Compare AUTL & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUTL
- CRGX
- Stock Information
- Founded
- AUTL 2014
- CRGX 2021
- Country
- AUTL United Kingdom
- CRGX United States
- Employees
- AUTL N/A
- CRGX N/A
- Industry
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- CRGX
- Sector
- AUTL Health Care
- CRGX
- Exchange
- AUTL Nasdaq
- CRGX Nasdaq
- Market Cap
- AUTL 625.4M
- CRGX 190.0M
- IPO Year
- AUTL 2018
- CRGX 2023
- Fundamental
- Price
- AUTL $2.63
- CRGX $4.59
- Analyst Decision
- AUTL Strong Buy
- CRGX Hold
- Analyst Count
- AUTL 5
- CRGX 7
- Target Price
- AUTL $9.32
- CRGX $5.33
- AVG Volume (30 Days)
- AUTL 1.8M
- CRGX 1.9M
- Earning Date
- AUTL 08-07-2025
- CRGX 08-11-2025
- Dividend Yield
- AUTL N/A
- CRGX N/A
- EPS Growth
- AUTL N/A
- CRGX N/A
- EPS
- AUTL N/A
- CRGX N/A
- Revenue
- AUTL $9,011,000.00
- CRGX N/A
- Revenue This Year
- AUTL $461.76
- CRGX $57.81
- Revenue Next Year
- AUTL $112.66
- CRGX N/A
- P/E Ratio
- AUTL N/A
- CRGX N/A
- Revenue Growth
- AUTL N/A
- CRGX N/A
- 52 Week Low
- AUTL $1.11
- CRGX $3.00
- 52 Week High
- AUTL $5.00
- CRGX $25.45
- Technical
- Relative Strength Index (RSI)
- AUTL 69.63
- CRGX 61.56
- Support Level
- AUTL $2.40
- CRGX $4.32
- Resistance Level
- AUTL $2.52
- CRGX $4.63
- Average True Range (ATR)
- AUTL 0.11
- CRGX 0.16
- MACD
- AUTL -0.00
- CRGX 0.04
- Stochastic Oscillator
- AUTL 85.97
- CRGX 76.44
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.